Ophthalmic Eye Dropper Market - Top Companies and Manufacturers

  • Report ID: 6681
  • Published Date: Nov 13, 2024
  • Report Format: PDF, PPT

Companies Dominating the Ophthalmic Eye Dropper Landscape

    Key players in the ophthalmic eye dropper market are employing several organic and inorganic tactics such as technological advancements, new product launches, mergers & acquisitions, strategic partnerships & collaborations, and regional expansion to earn more. Industry giants are investing heavily in research and development activities to introduce innovative solutions. They are also collaborating with other players, research organizations, and tech firms to introduce smart ophthalmic eye droppers. Such advanced droppers are widely adopted by tech-savvy patients.

    Some of the key players include:

    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Alcon Inc.
    • AdvaCare Pharma
    • Pfizer Inc.
    • PanOptica, Inc.
    • Bausch Health Companies Inc.
    • Dompé Farmaceutici S.p.A
    • Novartis AG
    • Prestige Consumer Healthcare Inc.
    • Sun Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

In the News

  • In October 2024, Orasis Pharmaceuticals announced that it secured USD 78 million in funding for the commercial launch of Qlosi 0.4% a pilocarpine hydrochloride ophthalmic solution.  Qlosi is an innovative corrective eye drop for the treatment of presbyopia in adults.
  • In April 2024, Viatris Inc. announced the launch of RYZUMVI 0.75% a phentolamine ophthalmic solution in the U.S. RYZUMVI is an FDA-approved eye drop for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists.

Author Credits:  Radhika Pawar


  • Report ID: 6681
  • Published Date: Nov 13, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global ophthalmic eye dropper market will be valued at USD 16.5 billion in 2025.

Expanding at a CAGR of 6.9%, the global market is expected to increase from USD 15.5 billion in 2024 to USD 36.7 billion by 2037.

Some leading companies are AbbVie Inc., Alcon Inc., AdvaCare Pharma, and Pfizer Inc.

The preserved multi-dose eye dropper segment is estimated to capture a high 49.0% of the market share through 2037.

North America is anticipated to hold 34.6% of the global market share through 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample